Quality of Life Research

, Volume 20, Issue 2, pp 255–262

Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials

  • Kathleen W. Wyrwich
  • Neesha Harnam
  • Julie C. Locklear
  • Henrik Svedsäter
  • Dennis A. Revicki
Article

DOI: 10.1007/s11136-010-9734-1

Cite this article as:
Wyrwich, K.W., Harnam, N., Locklear, J.C. et al. Qual Life Res (2011) 20: 255. doi:10.1007/s11136-010-9734-1

Abstract

Background and Aims

The Wilson–Cleary health outcomes model is a hypothesized pathway linking traditional clinical variables to health-related quality of life (HRQL). This study tested the application of the Wilson–Cleary model to a patient population with generalized anxiety disorder (GAD) using longitudinal clinical trial data.

Methods

These secondary analyses pooled data from three similar 8-week, placebo-controlled, double-blind, randomized, multicenter trials of quetiapine XR therapy in GAD. Relevant health assessments for the model concepts included the Clinical Global Impression-Severity of Illness, Hamilton Rating Scale for Anxiety, the Pittsburgh Sleep Quality Index and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. A lagged path model tested whether the hypothesized relationships at baseline and week 8 between the concepts of the adapted Wilson–Cleary model were consistent with the observed data.

Results

The resulting model fit the data (RMSEA = 0.077; CFI = 0.98; NFI = 0.96) and explained 56% of the variance in overall quality of life assessment at baseline and 69% of the variance in this assessment at week 8. Moderate to strong relationships between the adjacent hypothesized concepts support the specified model.

Conclusion

This adapted Wilson–Cleary model for health outcomes validated in GAD should improve the understanding and usefulness of health status measurements in this condition and increase the applications of this model to other clinical trial data.

Keywords

Generalized anxiety disorderWilson–Cleary modelHealth-related quality of lifeHealth assessmentPath analysisLagged model

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Kathleen W. Wyrwich
    • 1
  • Neesha Harnam
    • 1
  • Julie C. Locklear
    • 2
  • Henrik Svedsäter
    • 3
  • Dennis A. Revicki
    • 1
  1. 1.United BioSource CorporationBethesdaUSA
  2. 2.AstraZeneca Pharmaceuticals LPWilmingtonUSA
  3. 3.AstraZeneca R&DMölndalSweden